T cell boosting therapy expands into oncology

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Design Cells)
(Image: Getty/Design Cells)

Related tags: Oncology, Immuno-oncology, T cell receptor, T cells

US FDA grants orphan drug designation for Hyleukin-7, an immuno-oncology agent that boosts T cell production and functionality, for the treatment of ICL.

NeoImmuneTech’s Hyleukin-7 (rhIL-7-hyFc, NT-I7) was granted an orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of idiopathic CD4+ lymphocytopenia (ICL). The drug candidate also received an orphan drug designation from the European Medicines Agency in 2017.

Additionally, the T cell amplifier is being investigated for the potential treatment of cancer, in combination with current oncology therapies.

ICL is a rare disease that causes patients without HIV or any immunodeficiency to have persistently low CD4+ T lymphocyte counts. Individuals with ICL are at a high risk for developing certain types of cancer and recurrent infections.

According to the company, Hyleukin-7 is designed to increase a patient’s T cells and is predicted to broaden T cell receptor diversity, which could bolster T cell responses.

The drug candidate amplifies T cell immunity in the treatment of patients with cancer and ICL, therefore providing treatment opportunities for immuno-oncology combination strategies, potentially alongside anti-PD-(L)1 agents or chemotherapy.

The orphan drug designation comes after a Phase I trial in healthy participants and multiple ongoing dose-escalation trials in cancer patients showed a well-tolerated safety profile and dose-dependent increases of CD4+ and CD8+ T lymphocyte counts.

According to NeoImmuneTech, Hyleukin-7 has the potential to amplify and prolong anti-tumor activity, which could extend survival for cancer patients. It is being studied in clinical trials for solid tumors and hematologic malignancies, in addition to its indication for ICL.

Related news

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us


View more